Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-10-21 03:03 CEST (UTC+2h)
 

Fampridine [Design Issues]

posted by MaggieSantos - Portugal, 2017-09-20 13:05  - Posting: # 17821
Views: 541

Good morning,

We have been asked to perform a BE study on Fampridine.

I would like to confirm two informations. Does Fampridine is considered a NTI drug for EMA?

Considering a CI limit of 90-111% whats the recomende sample size for fampridine.

Do you know any good and free calculation site for BE?

Kind Regards

mMrgarida Barreto

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,396 Posts in 3,726 Threads, 1,074 registered users;
27 users online (0 registered, 27 guests).

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed